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Background: Cancer survivors and their informal caregivers (family members, close friends) often experience
significant impairments in health-related quality of life (HRQOL), including disruptions in psychological, physical,
social, and spiritual well-being both during and after primary cancer treatment. The purpose of this in-progress pilot
trial is to determine acceptability and preliminary efficacy (as reflected by effect sizes) of CBCT® (Cognitively-Based
Compassion Training) compared with a cancer health education (CHE) attention control to improve the primary
outcome of depressive symptoms and secondary outcomes of other HRQOL domains (e.g., anxiety, fatigue),
biomarkers of inflammation and diurnal cortisol rhythm, and healthcare utilization-related outcomes in both cancer
survivors and informal caregivers.
Methods: Forty dyads consisting of solid tumor survivors who have completed primary treatments (chemotherapy,
radiation, surgery) and their informal caregivers, with at least one dyad member with ≥ mild depressive symptoms
or anxiety, will be recruited from Tucson, Arizona, USA. Survivor-caregiver dyads will be randomized together to
complete either CBCT or CHE. CBCT is a manualized, 8-week, group meditation-based intervention that starts with
attention and mindfulness and builds to contemplative practices aimed at cultivating compassion to the self and
others. The goal of CBCT is to challenge unexamined assumptions about feelings and behaviors, with a focus on
generating spontaneous self-compassion and increased empathic responsiveness and compassion for others. CHE is
an 8-week, manualized group intervention that provides cancer-specific education on various topics (e.g., cancer
advocacy, survivorship wellness). Patient-reported HRQOL outcomes will be assessed before, immediately after
(week 9), and 1 month after CBCT or CHE (week 13). At the same time points, stress-related biomarkers of
inflammation (e.g., plasma interleukin-6) and saliva cortisol relevant for survivor and informal caregiver wellness and
healthcare utilization will be measured.
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Discussion: If CBCT shows acceptability, a larger trial will be warranted and appropriately powered to formally test
the efficacy of this dyadic intervention. Interventions such as CBCT directed toward both survivors and caregivers
may eventually fill a gap in supportive oncology care programs to improve HRQOL and healthcare utilization in
both dyad members.
Trial registration: Clinicaltrials.gov, NCT03459781. Prospectively registered on 9 March 2018.
Keywords: Cancer survivorship, Health-related quality of life, Compassion meditation, Dyadic interdependence,
Inflammation, Cortisol, Active controlBackground
Advancements in early detection and treatments have
dramatically improved prognosis for the majority of pa-
tients diagnosed with solid tumor cancers. Recent trend
data show that 5-year survival rates are improving for
those treated for colorectal (66%), prostate (99%), and
breast cancer (women, 90%) [1]. Despite these gains,
health-related quality of life (HRQOL) impairments re-
main significant for cancer survivors both during and
after treatment. For example, after diagnosis and the end
of primary treatment, survivors of colorectal, prostate,
and breast cancer are likely to experience elevated de-
pressive symptoms (i.e., 28% [2], 18% [3], and 10–25%
[4, 5], respectively), fatigue (23–73% [2, 6], 12–21% [7],
and 30–80% [8–10], respectively), and anxiety symptoms
(including fear of recurrence) [11–16].
While the focus on HRQOL in cancer survivorship is
often on cancer survivors themselves, informal care-
givers (hereafter referred to as caregivers; i.e., family
members and friends who provide supportive care for
cancer survivors) also suffer HRQOL impairments. A
sizable portion of these caregivers experience increased
depressive symptoms and distress, not just around the
time of diagnosis and during primary treatments, but
also after primary cancer treatments have ended for the
cancer survivor [17–19]. Impairments experienced by
caregivers are significant for several reasons. Caregivers
provide significant supportive care (as much as 60%) to
their loved one diagnosed with and treated for cancer
[19–21], and HRQOL impairments can undermine their
effectiveness in this role. Quality of life of caregivers
is important and significant in its own right, and
stress experienced by caregivers may have an impact
on stress-responsive physiology, including cortisol and
inflammation. These stress biological changes may ac-
company an increased risk for chronic medical and
psychiatric illness experienced by caregivers [22–24].
Although there are many interventions to improve
HRQOL for cancer survivors, there are few for care-
givers, and still fewer that engage both survivors and
caregivers together. The dearth of programs that engage
survivors and caregivers together is a significant gap.
Work by our group has shown that increased depressivesymptoms, anxiety, symptom distress (including fatigue),
and positive affect that breast (or prostate) cancer survivors
experience are interdependent with the same impairments
that their caregivers experience, and vice-versa [25, 26].
Caregivers are therefore much more than a “social back-
drop” to cancer and its treatment [25]. Instead, HRQOL is
shared by both members of a cancer survivor dyad, per-
haps by way of “emotional contagion,” or through the
multilevel phenomenon whereby stimuli from one individ-
ual results in a complimentary emotional or behavioral
state in another individual (i.e., the “common fate” model)
[27]. We believe that our findings suggest that interven-
tions to promote HRQOL in either cancer survivors or
their caregivers should be directed at both members of the
dyad simultaneously to leverage emotional contagion to
promote the sharing of positive affect, potentially dismant-
ling the possibility of shared negative affect.
CBCT® (Cognitively-Based Compassion Training) is a
manualized 8-week, meditation-based intervention that
cultivates empathy and prosocial capacity and enhances
perceptions of social connection and positive emotions
for others [28]. CBCT is “cognitively-based” in that it re-
lies on an analytical method of meditation to gain deeper
understanding of a particular topic [29]. The interven-
tion begins by teaching mindfulness practices and builds
on this heightened awareness to facilitate constructive
emotional states, self-compassion, and feelings of social
connectivity [28]. We have found that CBCT improves a
number of different HRQOL dimensions in breast can-
cer survivors, including symptoms of depression, fear of
cancer recurrence, and vitality [30]. We have also found
that CBCT has other health-related benefits in nonsurvi-
vors, including reduced stress-related inflammation in
young adults and foster care adolescents [30–36]. These
findings suggest that CBCT is likely to be feasible for
use in survivors of other solid tumor cancers and may
promote positive changes in key aspects of HRQOL in
the same individuals. However, CBCT has not been
tested before with survivors other than those of breast
cancer who have different treatments and prognoses, or
with caregivers of solid tumor cancer survivors. There-
fore, in the present pilot trial we will investigate accept-
ability of CBCT, as well as an active attention control
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solid tumor cancer survivors and their caregivers.
Besides acceptability of CBCT and CHE, we will also
evaluate effect sizes for the differences between CBCT
and CHE on several outcomes especially relevant for
survivors and caregivers. The primary outcome among
these will be depressive symptoms, a key domain of psy-
chological HRQOL. Secondary outcomes will include
other HRQOL domains (anxiety, positive affect, fatigue,
empathy, feelings of social connection), global HRQOL,
dyadic function, and self-compassion. We will also assess
stress-related biomarkers and healthcare utilization as
secondary outcomes. Considerable evidence, including
work by our group, suggests that HRQOL impairments
in cancer survivors are causally linked to changes in
stress-related physiological function, including diurnal
cortisol production and biomarkers of inflammation
(plasma interleukin (IL)-1β, IL-6, and tumor necrosis
factor (TNF)-α; peripheral blood mononuclear cell
(PBMC) nuclear factor-κB (NF-κB)) [37, 38]. HRQOL
impairments (e.g., depression) have also been found to
be associated with poor use of healthcare resources in
cancer survivors [39]. The current trial will begin to ex-
tend our earlier findings with breast cancer survivors to
survivors of other cancers, and CBCT will be con-
ducted for the first time in a form where both cancer
survivors and their caregivers take part in CBCT to-
gether. If CBCT and CHE are acceptable to survivors
and caregivers, a larger trial in the future will be justi-
fied. To avoid the possibility of a floor effect with the
outcomes assessed (especially psychological HRQOL; i.e.,
depression and anxiety), and because prior research with
CBCT suggests brain systems implicated in compassion
may show beneficial change when depression symptoms
improve while learning CBCT [34], the study will enroll
dyads with a survivor and/or caregiver with ≥ mild depres-
sive and/or anxiety symptoms (according to PROMIS
distress-depression or distress-anxiety four-item scales).
The overarching prediction of the current pilot trial is
that participation in CBCT or CHE will be acceptable to
solid tumor cancer survivors and their caregivers. We
will also capture effect sizes for outcomes noted above
for the comparisons of participants randomized to either
CBCT or CHE. The following aims guide the pilot trial.
Study aims and hypotheses
Aim 1 is to demonstrate acceptability of CBCT and CHE
for solid tumor cancer survivors and their caregivers. We
predict that both CBCT and CHE will be acceptable for
use with survivor-caregiver dyads, as reflected by > 75%
average attendance at weekly CBCT classes, and > 75%
average attendance at weekly CHE classes.
Aim 2 is to estimate effect sizes for the differences
between CBCT and CHE at weeks 9 and 13 onHRQOL-related outcomes including outcomes of psy-
chological HRQOL (depressive symptoms (primary out-
come), anxiety, positive affect, and self-compassion),
physical HRQOL (fatigue), and social HRQOL (empathy,
feelings of social connection/isolation, dyadic func-
tion) as well as global well-being. Differences between
groups at weeks 9 and 13 on HRQOL-related out-
comes will be used to inform sample size calculations
for a full-scale clinical trial.
Aim 3 is to estimate effect sizes between groups at
weeks 9 and 13 on stress-related biomarkers of inflam-
mation (plasma IL-6, IL-1β, TNF-α, NF-κB pathway acti-
vation), as well as diurnal saliva cortisol rhythm in
survivor-caregiver dyads randomized to CBCT compared
with survivor-caregiver dyads randomized to CHE. Dif-
ferences between groups at weeks 9 and 13 on bio-
marker outcomes will be used to inform sample size
calculations for a full-scale clinical trial.
Aim 4 is to estimate effect sizes for the differences be-
tween CBCT and CHE at weeks 9 and 13 on healthcare
utilization (i.e., keeping appointments, use of preventive
services, hospitalizations, and use of urgent care or
emergency department services), and patient activation
(i.e., motivation, knowledge, skills and confidence in
managing personal health). Differences between groups
at weeks 9 and 13 on healthcare utilization outcomes
will be used to inform sample size calculations for a
full-scale clinical trial.
Methods
Study design, allocation procedures, and blinding
This interventional study uses a randomized controlled
trial design to compare CBCT with CHE to determine
effect sizes in study outcomes (see below). Participants
review and sign the informed consent form in the pres-
ence of either the Principal Investigator or a study co-
ordinator after a script is read aloud to them that
describes the study. Enrolled dyads are randomized 1:1
in blocks of two dyads to either CBCT (n = 20 dyads) or
the attention control (n = 20 dyads). CBCT and CHE
groups are run concurrently. Group assignment to either
CBCT or CHE is revealed after the baseline (T1) assess-
ment is complete. This study protocol follows the Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines (see the SPIRIT checklist for
this protocol in Additional file 1). Enrollment began in
March 2018, and is recruiting at the time this report was
prepared. We are running 3–4 cohorts of CBCT and 3–4
cohorts of the CHE group over 24months, with 4–10 dyads
in each cohort. HRQOL and healthcare adherence assess-
ments as well as collection of biomarker samples are con-
ducted before (T1), immediately after either 8-week
intervention (T2), and then again 4–5weeks later (T3).
Overall study flow is depicted in Fig. 1. A study coordinator
Fig. 1 Diagram of study flow. CBCT® Cognitively-Based Compassion Training, CHE cancer health education
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College of Nursing. Participants are also contacted the day
before each assessment visit for a reminder, and to convey
information about finding their way to the assessment site.
If participants fail to complete study assessments at T2
(week 9), we attempt to collect data from them at T3 (week
13). Class attendance and at-home practice time (CBCT
group only) are collected as measures of intervention
engagement.
The randomization (allocation) sequence used to as-
sign dyads to CBCT or CHE is generated using a com-
puter program by someone not involved in other aspects
of the study procedures (see acknowledgements below).
Dyads are informed of their group assignment by a study
coordinator. The coordinator who informs participants
about their group assignment is not involved in recruit-
ment, scheduling of study assessments, or administration
of study assessments. The same coordinator only learns
about a particular dyad’s group assignment from the in-
dividual who generates the allocation sequence after thatdyad has completed T1 assessments. All other study
personnel who are not interventionists remain blinded
to group assignment throughout the study. Participants
are asked to not discuss their group assignment with
anyone other than a study coordinator who is not in-
volved in administration of study assessments. In the
event of an adverse event that is either related or unre-
lated to the trial unblinding will be permitted so that
other members of the study team (i.e., the Principal
Investigator or clinician co-Investigators) are able to
respond appropriately. Participation in the study may be
stopped if a participant is unable to complete a study as-
sessment per protocol because of health status changes.
Research ethics approval
All procedures have been reviewed and approved by the
University of Arizona Institutional Review Board (IRB)
and have been found to be acceptable according to rele-
vant policies of the University of Arizona as well as state
and United States federal regulations designed to protect
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changes made to the study protocol will be approved by
the IRB as a protocol amendment and communicated to
all members of the study team.
Participants
This study is enrolling survivors of solid tumor cancers
who have completed cancer treatment (except for hor-
monal therapies) and their caregivers. For the current
study, caregivers are defined as an individual (one care-
giver per survivor) identified by the survivor as either a
family member or close friend (i.e., fictive kin) who has
provided and/or continues to provide support to the sur-
vivor. Survivors and caregivers can be either gender, and
any race/ethnicity.
To be included in the study, cancer survivors and
caregivers must be: 1) aged 21 or older; 2) cognitively
oriented in time, place, and person; 3) able to speak and
understand English; and 4) able to travel to a centralized
location to attend CBCT or CHE group sessions. Inclu-
sion criteria specific to cancer survivors are that they
must have: 1) a solid tumor cancer diagnosis; and 2)
have completed cancer treatment (surgery, radiation,
chemotherapy) except for hormonal therapies (e.g., aro-
matase inhibitors, androgen suppression therapy) a
minimum of 3 months and a maximum of 10 years be-
fore starting CBCT or CHE. An inclusion criterion spe-
cific to caregivers is that they must be named by their
cancer survivor. Cancer survivor and caregivers are ex-
cluded from the study if they: 1) have a self-reported
diagnosis of a major mental illness (e.g., psychosis or un-
controlled major depression); 2) are a nursing home
resident; and 3) have an ongoing compassion meditation
practice (as determined by the Principal Investigator). In
addition to these inclusion criteria, either the survivor, the
caregiver, or both the cancer survivor and caregiver must
report at least mild anxiety (PROMIS distress-anxiety
four-item raw score > 6) and/or mild depressive symptoms
(PROMIS distress-depression four-item raw score > 6) to
be enrolled into the study. For eligible consenting partici-
pants, interventions start approximately 2 weeks after the
initial screening.
Participants for the study are being recruited from local
cancer advocacy organizations located in metropolitan
Tucson, Arizona, USA, as well as the University of Ari-
zona Cancer Center (UACC) located in Tucson. Partici-
pants will receive compensation for their participation in
the study: 20 USD for each assessment visit they complete,
and 20 USD for each intervention session they attend.
Study setting
All procedures for the proposed research (except saliva
collection) are completed at the University of Arizona
College of Nursing, including blood draws, self-reportassessments, and the 8-week intervention classes (CBCT
and CHE). Saliva (see biomarker methods below) is
collected in participants’ homes.
Study outcomes (measures)
For a complete overview of study outcomes according to
study visit schedule, please see Fig. 2 (arranged accord-
ing to SPIRIT guidelines) [32, 33, 40–57].
Intervention engagement/acceptability
Intervention engagement and acceptability will be mea-
sured weekly at each CBCT and CHE session by adher-
ence to intervention engagement requirements (class
attendance, home practice (CBCT only)) by both dyad
members. At-home practice will be recorded with a
structured paper form, divided into days of the week,
asking about practice time on a given day, and personal
reflections of each practice. To support accurate docu-
mentation of at-home practice, and based on our prior
experience with breast cancer survivors, we will use text,
email, and telephone reminders to accurately complete
the form shortly after completing a practice session [30].
We will also document rates of consent (before alloca-
tion) and retention of dyads (attending the majority of
intervention classes and completion of all study assess-
ment time points).
Health-related quality of life
Assessments of HRQOL defined in the study aims will
be measured with several quantitative scales (see Table 1)
[40–49]. Paper questionnaire forms will be inspected for
completeness by study staff immediately after they are
finished by participants, and participants will be asked to
respond to any items that are left blank.
Healthcare utilization
Healthcare utilization will be measured using the follow-
ing self-report assessments.
Healthcare utilization self-report questionnaire
This assessment, designed by us, captures appointment
keeping for oncologic, primary care, and noncancer spe-
cialty care (if needed), and closely follows approaches
used in previous studies of people who have cancer and/
or other chronic conditions [50, 51].
Patient activation
We will assess patient activation using the short version of
the Patient Activation Measure (PAM). The PAM consists
of 13 items that form an interval level, unidimensional,
Guttman-like scale to assess Hibbard’s four stages of acti-
vation [52, 53]. Items are statements about confidence, be-
liefs, knowledge, and skills about managing one’s health,
with responses as degrees of agreement or disagreement.
ll - - -
Fig. 2 Study schedule of events. *Primary outcome. CBCT® Cognitively-Based Compassion Training, CHE cancer health education, IL interleukin,
NF-κB nuclear factor-κB, PBMC peripheral blood mononuclear cell, TNF tumor necrosis factor
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properties and is predictive of most health behaviors and
many health outcomes [52, 53].
Stress-related biomarkers
Inflammatory biomarkers Plasma and PBMCs will be
obtained from blood drawn at all study assessment time
points (T1, T2, and T3; see below) between the hours of
13:00 and 16:00 by venipuncture into EDTA-coated vacu-
tainers. Plasma will be obtained by centrifugation, and
PBMCs obtained by Ficoll-Paque gradient separation.
Concentrations of IL-6, IL-β, and TNF-α in plasma will bebatch analyzed using a high-sensitivity magnetic bead
multiplex from R&D Systems. The PI’s laboratory has ex-
perience with multiplex assays for cytokines and has
found good agreement between cytokine concentrations
determined using multiplex assays and high-sensitivity
enzyme-linked immunosorbent assays (ELISAs) [54].
NF-κB will be batch analyzed in PBMCs collected at each
of the study time points using methods already established
in the PI’s laboratory [55–57]. PBMCs will undergo nu-
clear extraction procedures with a high salt/low salt treat-
ment before quantification of NF-κB binding to its DNA
consensus sequence using a chemiluminescent tran-
scription factor assay (Active Motif, Carlsbad, CA,
Table 1 Health-related quality of life assessments
Instrument name # items Response options Other information
Depression PROMIS short-form Depression-8aa 8 Never, rarely, sometimes, often, always Alpha 0.92; developed with IRT [40]
Anxiety PROMIS short-form Anxiety-8 8 Never, rarely, sometimes, often, always Very good reliability; developed
with IRT [40]
Fatigue PROMIS short-form 7-item Fatigue 7 Never, rarely, sometimes, often, always Alpha 0.87; developed with IRT [40]
Empathy Interpersonal Reactivity Index 28 5 responses from “does not describe
me well” to “describes me very well”
Four subscales: perspective-taking,
empathic concern, personal distress,
and fantasy); good reliability [41–43]
Social connection Social Connectedness Scale,
Revised
20 6 responses from “strongly agree”
to “strongly disagree”
Alpha 0.92 [44]
Global health-related
quality of life
Quality of Life Index 60 6 responses from “very satisfied” to
“very dissatisfied”, or from “very
important” to “very unimportant”
Alpha 0.87–0.97 (cancer survivors),
0.92–0.93 (informal caregivers) [45]
Positive affect Positive and Negative Affect
Schedule
20 Very slightly or not at all, a little,
moderately, quite a bit, and
extremely
Alpha 0.87 (positive scale) [46]
Dyadic function Relationship Assessment Scale 7 5 responses from “low satisfaction”
to “high satisfaction”
Alpha 0.86 [47]
Self-compassion Neff Self-Compassion Scale 26 5 responses from “almost never”
to “almost always”
Alpha 0.92 [48, 49]
aPrimary outcome
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genetic polymorphisms in this project. The NF-κB assay
assesses activation of this inflammatory signaling path-
way by measuring the degree to which its activated
form binds to a synthetic consensus sequence.
Diurnal saliva cortisol Participants will be asked to col-
lect their own saliva in the home setting at all study as-
sessment time points. Concentrations of cortisol and
C-reactive protein (CRP) in saliva will be determined
using ELISA kits from Salimetrics (State College, PA,
USA) according to the manufacturer’s instructions from
saliva samples collected using the Sarstedt Salivette
(Sarstedt, Nümbrect, Germany). The PI’s laboratory has
experience using both of these analytic techniques
[32, 33]. Participants will be provided with saliva col-
lection kits that will include detailed instructions to
collection saliva immediately on waking, and then in
the evening about 2 h before bed time. Saliva samples
collected for this study will not be analyzed for any
purposes other than those stated immediately above.
Interventions
Cognitively-Based Compassion Training
CBCT was designed at Emory University by one of the
authors (LTN), and is a secular adaptation of techniques
derived from traditional Tibetan Buddhist methods for
cultivating compassion known as lo-jong [58]. The first term,
lo or “mind”, refers to subjectivity, and jong refers to trans-
formation or reorientation. The goal of this “transformation
of subjectivity” is to temper egoistic self-centeredness (“self--
cherishing”) toward altruism (“other-cherishing”) [59].Throughout CBCT, topics and meditation practices
build upon one another and are designed to develop an
awareness of perceptions and attitudinal biases that can
result in self-preoccupation and self-centeredness, chal-
lenge unexamined attitudes and cognitions toward
other people, facilitate cognitive reappraisal to under-
stand individuals and distress within a broader perspec-
tive of the human condition, and stimulate corrective
affective experiences using visualizations and imagery
during guided meditations. Putatively, the process is de-
signed to reverse, or decondition, negatively valanced
thoughts, emotions, and behaviors harmful to oneself
and others, and to recondition (“transform”) them into
those that are more prosocial and beneficial to oneself
and others. Moving from self-centeredness to compas-
sion does not occur rapidly, however. Therefore, CBCT
follows a step-by-step process toward the final goal of
inclusive and engaged compassion.
Over the course of 8 weeks there will be a total of
eight CBCT sessions, one per week, led by the instructor
(SED) who is certified by the CBCT training program at
Emory University. Participating dyads will attend the
weekly CBCT classes together, which we believe will be
critical to make concepts salient for both the survivor
and caregiver in each dyad. Each weekly session will last
for about 120 min and will begin with a brief welcome
meditation. This will be followed by a didactic phase in
which the instructor will articulate goals and content of
the current week, followed by a group discussion facili-
tated by the instructor. Group discussions will center on
the challenges of cancer, cancer survival, and caregiver
responses. All sessions combine lecture, discussion,
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will end with a 20–30min meditation guided by the in-
structor and specific to the topic of the week. In between
weekly meetings, dyads will be encouraged to practice a
minimum of 10min per day at home, and together as a
dyad if possible, using the provided audio recording.
A study coordinator will call participants once per
week, to remind them to practice at home, and also to
attend the next CBCT class. Our prior work suggests
that participants who practice an average of 3.1 sessions
per week (10 min minimum per session) tend to exhibit
meaningful changes in various outcomes including de-
pressive symptoms, self-compassion, and inflammatory
markers. Home practice will be encouraged by providing
dyads with printed narrative summaries of weekly les-
sons, as well as guided meditation audio recordings de-
veloped by the Emory CBCT program, and applied for
the current trial by the CBCT instructor (SED). Each
week, participants will be asked to complete a CBCT
practice log to assess their home practice, and to gather
information on their engagement with CBCT. The
course is divided into six modules, taught across eight
sessions that meet for no more than 120 min, plus time
for personal practice between sessions. All sessions com-
bine lecture, discussion, experiential exercises, and re-
flective practice.
Week 1: resting in a moment of nurturance and
developing attentional stability and clarity (module I)
Physical relaxation and focused attention training aid in
mental stability and attention regulation and lead to
concentration and later clarity of mental contents, states,
and processes. Week 1 reviews confidentiality, defines
compassion and its benefits, provides instruction in cor-
rect meditation posture, diaphragmatic breathing, and
relaxation of muscle tension. This is followed by visual-
izing a remembered moment of nurturance that recalls
the experience of compassion by a caregiver or caring
other to prime the practitioner in feelings of safety and
security. Last, the first mindfulness meditation practice
(shamatha) is introduced and uses the breath as an ob-
ject to focus attention for increasingly longer periods of
time. These opening practices are the starting point of
all subsequent CBCT meditation practice.
Week 2: insight into the nature of mental experience
(module II) The felt experience of compassion is one of
kindness, connection, and unconditional positive regard.
Cognitions, often with a negative emotional charge, are
impermanent and transient, change rapidly, and can be
observed as such. Week 2 reiterates the opening prac-
tices of the first week, and introduces the second mind-
fulness meditation practice (vipassana) to develop open
awareness of subjective experience throughnonjudgmental, nonreactive observation of the fluctuat-
ing (and impermanent) nature of thought, sensory ex-
perience, and emotion. This practice aids the
participant in distinguishing internal mental experi-
ences and external reality and creates a greater gap be-
tween an experience and the reaction to that
experience, thus allowing for more deliberate choice in
response or behavior. The technique is included in all
subsequent CBCT meditation practice.Week 3: self-compassion (module III) Before compas-
sion can be expressed to others, CBCT holds that one
must first understand and reduce causes of distress in
oneself, as well as attune to a sustained attitude of
kindness toward the self. The assumption that all
people share the common human desires for happiness,
well-being, and freedom from distress is discussed, yet
both external and internal conditions can interfere.
Thus, causes of both external and internal interference
need to be identified, along with learned perceptions
and cognitive appraisals that accompany them. Con-
cordant attitudes (e.g., narrow self-centeredness and
self-preoccupation) and behaviors (e.g., (egoic) attach-
ment and aversion, rumination, addiction, and avoid-
ance) that can sustain faulty appraisals and that are
potentially harmful require insight, reappraisal, and
corrective emotional experience. Introspection, resolve,
and commitment are then required for ongoing im-
provement. Week 3 introduces analytic meditation
practice (as opposed to mindfulness practice) to iden-
tify and assess conditioned and habitual patterns of
cognitions and appraisals contributing to distress to
promote a resolution to correct these habits as they are
identified.Week 4: developing equanimity and impartiality
(module IV) CBCT holds that, in the universal desire
for happiness, well-being, and freedom from distress, all
individuals are alike; there are no differences among
them (common humanity). Partiality and bias not only
harm those regarded as adversaries or enemies, but also
those regarded as loved ones since bias ultimately dis-
torts interactions with others. Week 4 counters the par-
ticipants’ learned attitudes of prejudice and partiality
through continuing reflection on the common human
desires for well-being and freedom from distress.
Through guided analytical meditation practice, recog-
nition of this commonality is promoted by visualizing
people in the categories of friend, adversary, and
stranger, with the goal of increasing identification
with them (and thus empathic understanding) and of
reducing indifference or excessive liking or disliking
of some over others.
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(module V) CBCT holds that all people exist in an in-
terconnected system, a web of interdependence for all
needed resources and benefits. Recognition of this inter-
dependence, in particular the high degree of dependence
one’s well-being has on the efforts of others, decreases
perceptions of interpersonal distance and social isolation
(disconnection) and can lead to a sense of appreciation
and gratitude for the beneficence of others, both familiar
and unknown, as well as the hidden benefits that are
often derived from adversaries. Week 5 explores inter-
connection and interdependence and the appreciation of
others. Analysis and reflection during meditation exam-
ine the benefits received from others, even those re-
ceived from adversaries. Further meditation practice
guides the participant in visualizing extending appreci-
ation and gratitude to an ever-widening circle of others.Week 6: affection (module V) The CBCT model con-
tends that experiences of appreciation and gratitude lead
to feelings of endearment, or warm affection. Warmth,
together with identification (see module IV), stimulates
empathy, or the recognition that others, too, experience
distress and its causes. Week 6 introduces affection for
others based on their beneficence and also their similar-
ity to oneself in wanting well-being yet often experien-
cing distress. Relating to others with profound affection
and endearment then becomes the preconditions for em-
pathy; in turn, empathy can catalyze compassion. Medita-
tive reflection is guided to recall the kindnesses of others,
their similarities to oneself (“just like me”), and to
strengthen endearment and affection towards them. Fur-
ther meditative reflection is guided on the drawbacks of
egoistic attitudes to lessen self-centeredness.Week 7: empathetic concern and engaged compassion
(module VI) Once insight into the causes of distress
(week 3) is combined with affection toward and em-
pathic understanding of others (week 6), CBCT holds
that compassion naturally ensues. Week 7 focuses on sus-
taining the spontaneous empathetic concern that naturally
arises when these two conditions are present: 1) holding
someone with deep affection and warm-heartedness; and 2)
attuning to their dissatisfaction, distress, and vulnerability.
To sustain the emerging motivation to alleviate their dis-
tress (while simultaneously acknowledging one’s limitations
and boundaries via self-compassion), week 7 provides in-
struction to attune to this compassionate love as an image
of energy or light, radiating outward and including first our
family and friends and then increasingly others. Instruction
guides the practitioner in wishing compassion as a desirable
thought of “how wonderful it would be if others were happy
and free from dissatisfaction”.Week 8: empathic concern and engaged compassion
(module VI) When a genuine desire for compassion is
deepened and accompanied with a determined motiv-
ation to help others when possible, the final step of
CBCT is considered to be activated or engaged compas-
sion. Continued practice helps strengthen all of the prior
skills and insights meant to support an embodied com-
passionate responsiveness toward others. In week 8, class
exercises promote group closure, and a final comprehen-
sive meditation practice is conducted. The same guided
meditation is used as in week 7, but more emphasis
during reflection is placed on phrases that promote a
move from simply wishing others happiness and free-
dom from distress to a motivational readiness to as-
sist whenever possible (“may they be happy and free
from dissatisfaction”).
Cancer health education
The cancer health education (CHE) intervention is an
adaptation of the in-person attention control called Health
Discussion, a protocol used previously by our group (LTN
and TWWP) [34] that incorporates select components
from a telephone-based health education program also
used previously by us (TAB and CS) [60, 61]. CHE focuses
on topics relevant to health and cancer for survivors and
caregivers including cancer advocacy, health and cancer
biology, nutrition, lifestyle interventions such as physical
activity and goals for physical activity, the importance of
good sleep, the impact of stress, and mental health and
social support.
Over the course of 8 weeks there will be a total of
eight sessions, one session per week, similar to CBCT.
As with CBCT, each session will last for approximately
120 min and will include a combination of lecture, group
discussion, and experiential exercises. CHE is a good
control condition for a trial investigating the benefits of
CBCT for several reasons. First, like CBCT, CHE in-
volves building new social contacts while also discussing
and learning new topics relevant for solid tumor cancer
survivors and their caregivers. Second, also like CBCT,
CHE requires individuals to travel to a central location
to receive the intervention. However, unlike CBCT, CHE
does not involve training around meditation, or struc-
tured discussions about compassion or kindness.
Week 1: cancer advocacy This module begins with a
discussion on cancer advocacy that includes the defin-
ition of cancer advocacy, how to be an advocate for your
own cancer care throughout survivorship, how to be an
advocate for others with cancer, and how to approach
public interest advocacy for cancer. This module also dis-
cusses current events related to cancer, trends about can-
cer diagnoses, and the latest science and research about
cancer (e.g., the Cancer Moonshot). At the conclusion of
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of the major themes of cancer advocacy and the signifi-
cance of cancer advocacy for promoting the wellness of
the self, family, and society, and cancer research.
Week 2: health through the lifespan This module pro-
vides an overview of the biology of cancer, how cancer is
defined, how cancer is treated, and the side effects of
cancer treatments. Also reviewed are topics relevant to
maintaining a healthy lifestyle over the lifespan including
leading causes of mortality besides cancer, brain and
mental health, and health screenings. At the conclusion
of this module participants will be familiar with the lead-
ing causes of death and avoidable causes of death, the
role of general health habits, the importance of health
screenings, and the relevance of mind-body connections
for health and cancer survivorship.
Weeks 3 and 4: nutrition The first week of this module
focuses on basic components of food such as carbohy-
drates, proteins, and fat. Whole grains, hydration, and
caffeine are also discussed, as well as essential nutrients
and dietary fiber. The second week provides an overview
of healthy diet tips, serving sizes, and factors that con-
tribute to unhealthy eating. Key topics in the second
week include nutrition related to obesity, healthy serving
sizes, nutritional “trade-offs”, healthy grocery shopping,
and tips for maintaining a healthy diet. At the conclu-
sion of this module participants will have an understand-
ing of food components, as well as basic strategies to
maintain good nutrition to promote health, including in
cancer survivorship.
Week 5: physical activity This module reviews the im-
portance of physical activity in survivorship and also the
importance of physical activity for the wellness of non-
cancer survivors across the lifespan. This module pro-
vides an overview and explanation of the basic
components, principles, and health benefits of physical
fitness. Information for developing and implementing a
personal fitness plan and goals are also presented. The
module concludes with practical tips for exercise, for ex-
ample staying fit while traveling. It will also address the
consequences of a lack of exercise (e.g., obesity), the
health benefits of exercise (e.g., mental wellness, healthy
aging, cardiovascular wellness), lactic acid, muscle burn-
ing and soreness, planning an exercise schedule, and ex-
ercise nutrition. At the conclusion of this module
participants will have an understanding of exercise ba-
sics, the relationship between exercise and wellness, and
how to better incorporate exercise in their own lives.
Week 6: sleep This module provides an overview of the
sleep cycle, the benefits of sleep, common sleep disorders,and tips for better sleep. Topics considered also include
the neuroscience mechanisms of sleep, common sleep dis-
orders, and tips for diet to promote healthy sleep, includ-
ing for survivors. By the end of the module participants
will understand the mechanisms of sleep, why sleep is im-
portant for good health (including in survivorship), and
how to get better sleep.
Week 7: stress This module reviews the concept of stress
and how stress is known to impact health, including the
biological mechanisms involved. Topics discussed include
the definition of stress, a review of “America’s most
stressed out cities”, types of stress (distress and eustress),
negative effects of chronic stress, and basic ways to cope
with stress. Of note, this module will not provide partici-
pants with a comprehensive stress management plan. In-
stead, the coping strategies for stress considered will be
limited to general topics such as good sleep, physical ac-
tivity, and diet (to synergize with earlier CHE modules).
Week 8: mental health and social support This mod-
ule provides a broad overview of mental health disorders
(e.g., depression, anxiety disorders, eating disorders), as
well as disorders that many survivors and caregivers ex-
perience. The health-related consequences of loneliness
and the benefits of social interaction are also reviewed.
This module also introduces the concept of social capital
and explores the impact of social networking sites. By the
end of the module participants will have a general under-
standing of mental health disorders and how social con-
tact can promote wellness for survivors and caregivers.
Power, data management plan, and analytic plan
As a preliminary effort, this study’s sample size was not
determined based on power considerations. The goal is
to estimate the effect sizes for the differences between
the CBCT and CHE in the specified outcomes at weeks
9 and 13, so that the next definitive trial can be formally
powered using the effect sizes estimated in this pilot
study. Therefore, the sample size for this study (n = 40
dyads (80 participants total); CBCT n = 20, CHE atten-
tion control n = 20) is based on the number of cancer
survivor-caregiver dyads projected to meet inclusion cri-
teria and complete the entire study protocol in the study
timeframe. The estimate of the effect size will be used to
power the definitive trial, provided that the estimate falls
into the range of clinically significant differences of 1/3
of the standard deviation or greater [62, 63]. The rigor
of the proposed pilot randomized controlled trial design
(i.e., having the CHE attention control) will secure the
attribution of the effects to the intervention.
Questionnaire total scores, biomarker data, and other
relevant endpoints (e.g., class attendance) will be entered
into the study database and managed in SPSS (IBM
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be summarized using the number of completed sessions.
For Aim 1 analysis (Hypothesis 1), acceptability will be
measured by attendance at weekly classes. Acceptability
will be determined as > 75% average attendance at
weekly CBCT classes and > 75% average attendance at
weekly CHE classes. For the other aims, both unadjusted
and adjusted effect sizes will be estimated. Estimates of
the unadjusted effect sizes will be computed as differ-
ences between sample means of two study groups at
each time point divided by the pooled standard devi-
ation. Furthermore, to reflect longitudinal design and in-
form planning of the larger definitive trial, we will
estimate the effect sizes adjusted for repeated measures
and inclusion of covariates. For Aim 2 analysis, two re-
peated measures of HRQOL outcomes will be entered
into a linear mixed effects model with the following co-
variates: outcome measure at baseline, study group, time
(week 9 or week 13), and group by time interaction. The
least square (LS) means according to the levels of the
interaction term will be output from the model, and ef-
fect sizes at each time point will be estimated as differ-
ences between the LS means divided by the adjusted
standard deviation. Separate models will be fit for each
survivor outcome and each caregiver outcome. We will
use the same approach to estimate effect sizes for
stress-related biomarker outcomes and associated hy-
potheses (Aim 3). A similar approach will also be
employed in the analysis for Aim 4 to estimate effect
sizes for healthcare utilization-related outcomes, except
that generalized linear mixed effects modeling will be
used for the analysis of two repeated measures, with the
appropriate error distributions specified based on ob-
served distributions of different health service use out-
comes (counts of health services use, kept appointments,
and patient activation).
Data handling
All study material including source documents and case-
books will be stored in a secured room at the University
of Arizona College of Nursing or on a secure computer
server or personal computer that are compliant with the
United States Health Insurance Portability and Account-
ability Act (HIPAA) and that can only be accessed by
study researchers. Data collected and study forms com-
pleted during assessment visits will be stored by study
number, not by subject name. A paper copy list linking
subject names to their subject numbers will be stored
separately from all other study documents. Study mate-
rials including electronic data and study consent forms
will be maintained for 6 years after the conclusion of the
project. Aggregated results will be presented at professional
conferences, published in appropriate scholarly journals,
and provided to study participants upon request. The studyPrincipal Investigator as well as co-Investigators will have
access to the final study dataset, and no contracts are re-
quired to regulate this access.
Data monitoring
It is possible that some of the participants may develop
psychiatric and/or medical problems from screening to
enrollment to after study end (up to 3 months later).
Also, although not expected, it is possible that blood
draws may result in adverse events for some partici-
pants. We have therefore elected to use the Data Safety
Monitoring Board (DSMB) at the University of Arizona
College of Nursing for this study. This DSMB will pro-
vide independent oversight to further promote the pro-
tection of human subjects and the overall integrity of
the study. Once every 6 months, the DSMB will review a
report from the study that includes: 1) the number of
participants who signed consent for the study; 2) the
number of dropouts; 3) reasons for these dropouts; 4)
any safety concerns or adverse events (i.e., solicited and
spontaneously reported adverse events and other unin-
tended effects of trial interventions or trial conduct); 5)
an up-to-date consent form; and 6) measures taken to
protect confidentiality (e.g., data storage, use of coded
ID numbers, etc.). After reviewing this information, the
DSMB will issue its own report summarizing any serious
and unexpected adverse events or other unanticipated
problems that involve risk to study participants, and
whether these appear related to the study-based research
assessment protocol. Given the nature of the interven-
tion and active attention control group, this study does
not have a plan for interim analyses. Analyses guided by
hypotheses noted above will only take place after all par-
ticipants have completed the study protocol.
Discussion
This trial will be the first to determine acceptability of a
compassion meditation-based intervention (CBCT) in
dyads consisting of solid tumor cancer survivors and
their caregivers. We believe the trial will be the first step
toward demonstrating that CBCT is especially worth-
while for cancer survivor-caregiver dyads for several rea-
sons. First, CBCT has already been shown to improve
various dimensions of HRQOL for breast cancer survi-
vors [30]. Second, both impairments in HRQOL and
affect have been found to be interdependent between
cancer survivors and their caregivers [25, 26, 64] and, if
CBCT improves HRQOL in one dyadic member, it may
transfer to the other member. Third, unlike other medita-
tion programs that only include mindfulness, CBCT actively
incorporates the intellectual analysis of how individuals are
interconnected with others while encouraging a move away
from egoistic self-centeredness and preoccupation. Thus,
among meditation programs available for cancer survivors
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courage healthy interconnectedness between cancer survi-
vors and their caregivers to improve HRQOL of the dyad.
The current trial is also poised to be a first step toward re-
vealing an interdependence in stress-related biomarkers
within the dyad (with a fully powered trial), including their
change over the course of the interventions. To the best of
our knowledge, an interdependence of cortisol or inflamma-
tory biomarkers has never been demonstrated before in can-
cer survivor-caregiver dyads.
Considerable evidence supports the inclusion of
stress-related biomarkers in the current pilot study. Breast
cancer survivors have been found to have increased circu-
lating concentrations of key inflammatory biomarkers that
positively correlate with fatigue [65–71]. Severity of major
depression features have also been associated with inflam-
matory biomarkers, including IL-6, in cancer survivors
[72], and our group has found that NF-κB activation in
circulating immune cells is elevated in breast cancer survi-
vors and is positively associated with fatigue and depres-
sion [55]. With respect to HRQOL impairments of
caregivers, there is also a rich science on how inflamma-
tion is causally linked with quality of life impairments ex-
perienced by noncancer survivors [73, 74], although
research that is focused exclusively on caregivers of cancer
survivors is not conclusive [22, 75, 76]. For cortisol, sig-
nificant distress in breast cancer survivors has been asso-
ciated with dysregulation of the hypothalamic-pituitary
adrenal axis, most frequently manifested as reduced vari-
ation in cortisol rhythm from morning (when cortisol is
normally high) to evening (when cortisol is normally
low) [77]. Psychological distress has been found to be
associated with flattening of the diurnal cortisol slope
in numerous patient populations, including those with
cancer [78–81]. Previous research has documented
that a flatter cortisol slope, or abnormal diurnal corti-
sol rhythm, has been associated with fatigue [82],
tumor progression and reduced survival [83, 84], de-
pression [80, 85], and negative psychosocial outcomes
in breast cancer survivors [86–89].
There is also a strong rationale to assess healthcare
utilization in the current study, especially the dimension of
patient activation. Activated patients are those with the mo-
tivation, knowledge, skills, and confidence to make effective
decisions in managing their health. Those with low activa-
tion are typically passive recipients of care and do not be-
lieve in the need for an active patient role. Those who are
highly activated are proactive about their health and engage
in many recommended health behaviors. Activation, how-
ever, is not either/or. A widely used developmental model
of activation involves four stages: 1) believing the patient
role is important; 2) having the confidence and knowledge
necessary to take action; 3) actually taking action to main-
tain and improve one’s health; and 4) staying the courseeven under stress [52, 53]. Correlational studies have found
patient activation to be related to healthy lifestyle behaviors
(e.g., physical activity, eating fruits and vegetables), appro-
priate use of healthcare services (e.g., having fewer hospital-
izations), and self-management of chronic conditions (e.g.,
diabetic eye examinations, recording blood pressure read-
ings, HbA1c control). Other studies show patient activation
to be a modifiable characteristic, and that interventions can
increase self-management capacities and health service use.
There are several practical and operational challenges
worth noting here that have already been encountered
by this research team. First, unlike other wellness pro-
grams for cancer survivors, CBCT critically involves the
coparticipation of a caregiver. Although for many cancer
survivors a caregiver may be easy to name, and easy to
“bring along” for many cancer survivors, for other survi-
vors there are scheduling problems or the caregiver
changes his/her mind about participating which can
affect the effectiveness of CBCT for the dyad. We are ac-
tively working to make the trial available to as many
dyads as possible by scheduling sessions at times that
work best for all, and if a survivor is unable to name a
caregiver, we do not enroll them but refer them to other
wellness resources. Second, based on our experience
with research involving CBCT in other populations (e.g.,
healthy community-dwelling adults, foster care chil-
dren), maintaining engagement of dyads randomized to
CHE may be a challenge. We have therefore included a
complimentary CBCT course for all dyads randomized
to CHE shortly after the last study assessment time
point to encourage study participation.
In summary, the trial presented here will elucidate
whether CBCT is acceptable and feasible for cancer
survivor-caregiver dyads, and if CBCT is associated with
improvements in HRQOL measures, biomarkers of in-
flammation, cortisol diurnal rhythm, and healthcare
utilization. The work in this trial will result in a larger,
well-powered trial and may result in the addition of CBCT
to supportive oncology care programs to improve HRQOL
in both members of the survivor-caregiver dyad.
Trial status
The protocol date is 30 March 2018 and is currently ap-
proved by the Human Subjects Protection Program at the
University of Arizona (1618 E. Helen St., P.O. Box 245,137,
Tucson, AZ 85724–5137, USA; tel. 520 626 6721). The
original protocol approval date was 1 December 2017. Re-
cruitment for the trial began on 14 March 2018, after first
posting on clinicaltrials.gov as NCT03459781. At the time
this report was submitted the trial was recruiting partici-
pants. Recruitment as well as all other procedures for the
trial is anticipated to conclude by September 2019. This
study protocol reports study protocol version 1.2, which
includes stress-related biomarkers.
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